Genitourinary (GU) Cancers Symposium

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

By

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

By

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

By

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

By

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

By

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

Early Tumor Shrinkage With Cabozantinib Improves Survival in RCC

Early Tumor Shrinkage With Cabozantinib Improves Survival in RCC

By

New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

By

Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

By

As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.

Obesity Linked With Improved Survival in mCRPC

Obesity Linked With Improved Survival in mCRPC

By

Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.

Radium-223 Use in mCRPC Differs By Race

Radium-223 Use in mCRPC Differs By Race

By

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

By

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

By

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

PCa Genomic Test May Predict Outcomes More Accurately in African-American Men

By

The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.

Newer mCRPC Drugs Led to Longer Survival in African American Patients

Newer mCRPC Drugs Led to Longer Survival in African American Patients

By

The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

Non-urothelial Bladder Cancer Type Affects Disease-Specific Survival

By

Patients with bladder adenocarcinomas have the best survival, whereas those with small cell carcinomas of the bladder have the worst.

Adverse Prostate Cancer Pathology Accurately Predicted With MRI

Adverse Prostate Cancer Pathology Accurately Predicted With MRI

By

Multiparametric MRI has high positive and negative predictive values for extracapsular extension, seminal vesicle invasion, lymph node involvement, and high-risk Gleason score.

Urologic Cancer Surgery Readmission Rate Highest for RC

Urologic Cancer Surgery Readmission Rate Highest for RC

By

In a study, nearly 20% of radical cystectomy patients were readmitted for complications within 90 days compared with 1.9% and 5.9% for radical prostatectomy and radical nephrectomy, respectively.

Early Prostate Cancer Salvage ADT Therapy Better

Early Prostate Cancer Salvage ADT Therapy Better

By

Among men who had PSA failure following radiation therapy for localized PCa, those with a long PSA doubling time had an increased risk of PCa mortality if they started androgen-deprivation therapy later.

Prostate Cancer Pathologic Features Worse in Blacks

Prostate Cancer Pathologic Features Worse in Blacks

By

Black men undergoing radical prostatectomy for prostate cancer are more likely to have indications for adjuvant radiotherapy compared with white men.

Statin Use May Improve Survival in Advanced Prostate Cancer

Statin Use May Improve Survival in Advanced Prostate Cancer

By

Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

Negative Repeat Biopsy in PCa Active Surveillance a Positive Sign

By

In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

Earlier Prostate Cancer Drug Use in CRPC Cuts Metastasis Risk

By

In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.

Testosterone Therapy May Reduce PCa Risk in Hypogonadal Men

Testosterone Therapy May Reduce PCa Risk in Hypogonadal Men

By

In a study of hypogonadal men, those who received testosterone therapy had a lower incidence of prostate cancer than those who did not.

Renal and Urology News Articles

Sign Up for Free e-newsletters